Who Is C2 Therapeutics

Delivering A Better Approach to Barrett’s: CryoBalloon® Ablation Systems for ablation of Barrett’s esophagus

About Us

Founded in 2007 and headquartered in Redwood City, California, C2 Therapeutics developed the C2 CryoBalloon® Ablation System for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s esophagus with dysplasia. Acquired by Pentax Medical – a division of HOYA Group – in January 2017, C2 Therapeutics continues to innovate and enhance its C2 CryoBalloon® Ablation System as a new standard for simplicity in the eradication of esophageal disease.

Our Technology

The technology comprises a through-the-scope, highly compliant balloon catheter that is simultaneously inflated and cooled by an inert cryogen delivered through a small disposable handheld unit. Operation is intuitive, fast and cost-effective. The C2 CryoBalloon® Ablation System eliminates the need for precise sizing, multiple deployment steps, and controller units.

MKTG 1069 REV A